A Trial for HER2 Positive Breast Cancer Patients With Metastatic Disease

Phase 2CompletedNCT00191373

Eli Lilly and Company66 enrolled

Overview

This phase II trial that includes Gemcitabine 1,250mg/m2 to be administered over approximately 30 minutes on days 1 and 8, every 21 days and Trastuzumab 8 mg/kg IV to be administered over 90 minutes on day 1 of the first cycle, then 6mg/kg as a 30 minute infusion administered on subsequent cycles.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Breast Neoplasms Cancer of the Breast Breast Cancer

Interventions

GemcitabineDRUG

TrastuzumabDRUG

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease * Tumors tested by IHC must be 3+ positive for HER2 overexpression. Tumors tested by FISH must be positive by the specific FISH assay for genetic amplification of HER2. Tumors that are 3+ by IHC but negative by FISH assay are ineligible * Patients must have measurable disease * Patients may NOT have received prior chemotherapy or prior trastuzumab therapy for metastatic breast cancer. * Patients may have received prior chemotherapy and/or hormonal therapy for early stage breast cancer, including taxane-based chemotherapy regimens. Patients may NOT have received trastuzumab in the adjuvant setting unless disease free interval from completion of trastuzumab to time of relapse is greater than 12 months. Exclusion Criteria: * Patients who have had prior gemcitabine chemotherapy and adjuvant trastuzumab and had less than 12- month disease free interval * Patients with known leptomeningeal carcinomatosis

Locations (13)

Outcomes

Primary Outcomes

- Overall response rates

Secondary Outcomes

Time to disease progression,Time to treatment failure, Overall survival, Toxicity of the combination

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Hot Springs, Arkansas, United States

Pine Bluff, Arkansas, United States

Redding, California, United States

For additional information regarding investigative sites for this trial, contact 1-877-CT-LILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Hollywood, Florida, United States

Plantation, Florida, United States

Baltimore, Maryland, United States

Voorhees Township, New Jersey, United States

Philadelphia, Pennsylvania, United States

Pittsburgh, Pennsylvania, United States

Knoxville, Tennessee, United States

...and 3 more locations